PTGX (STOCKS)
Protagonist Therapeutics, Inc
$112.460000
+2.680000 (+2.44%)
Prev close: $109.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Dinesh V. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,236.32M
- Employees
- 130
- P/E (TTM)
- -62.35
- P/B (TTM)
- 10.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.05 | $-0.54 | +0.5935 | +109.20% |
|
Dec 2025 (Q4)
|
$-0.69 | $-0.50 | -0.1917 | -38.47% |
|
Sep 2025 (Q3)
|
$-0.62 | $-0.65 | +0.0318 | +4.88% |
|
Jun 2025 (Q2)
|
$-0.55 | $-0.59 | +0.0400 | +6.78% |
Financial Statements
| Revenues | $74.06M |
| Benefits Costs and Expenses | $189.44M |
| Costs And Expenses | $189.44M |
| Operating Expenses | $216.53M |
| Research and Development | $170.14M |
| Other Operating Expenses | $46.39M |
| Operating Income/Loss | -$142.47M |
| Income/Loss From Continuing Operations After Tax | -$114.71M |
| Income/Loss From Continuing Operations Before Tax | -$115.38M |
| Income Tax Expense/Benefit | -$664.00K |
| Net Income/Loss | -$114.71M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$114.71M |
| Net Income/Loss Available To Common Stockholders, Basic | -$114.71M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.81 |
| Diluted Earnings Per Share | -$1.82 |
| Basic Average Shares | 192,525,242 |
| Diluted Average Shares | 197,930,013 |
| Assets | $697.46M |
| Current Assets | $613.46M |
| Noncurrent Assets | $84.00M |
| Fixed Assets | $3.78M |
| Other Non-current Assets | $80.23M |
| Liabilities | $41.99M |
| Current Liabilities | $34.55M |
| Accounts Payable | $8.44M |
| Other Current Liabilities | $26.11M |
| Noncurrent Liabilities | $7.44M |
| Equity | $655.47M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $655.47M |
| Liabilities And Equity | $697.46M |
| Net Cash Flow From Operating Activities | -$116.64M |
| Net Cash Flow From Operating Activities, Continuing | -$116.64M |
| Net Cash Flow From Investing Activities | $135.96M |
| Net Cash Flow From Investing Activities, Continuing | $135.96M |
| Net Cash Flow From Financing Activities | $34.80M |
| Net Cash Flow From Financing Activities, Continuing | $34.80M |
| Net Cash Flow | $54.12M |
| Net Cash Flow, Continuing | $54.12M |
| Comprehensive Income/Loss | -$115.07M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$115.07M |
| Other Comprehensive Income/Loss | -$74.46M |
| Other Comprehensive Income/Loss Attributable To Parent | -$354.00K |